Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D‐phenylalanyl‐N‐(3‐chlorobenzyl)‐L‐prolinamide is a synthetic small molecule dipeptide derivative with the molecular formula C21H24ClN3O2 and a molecular weight of approximately 385.9 g/mol[1][4][5]. It is primarily studied as an experimental compound and has not been approved for clinical use in any country[2][4]. The compound acts as a prothrombin inhibitor, binding to thrombin and thereby preventing the conversion of fibrinogen to fibrin, which is essential for blood clot formation. This mechanism suggests potential utility in modulating hemostasis and inflammatory responses[4]. Its main applications have been in research settings, including use as a catalyst in asymmetric synthesis due to its ability to form hydrogen bonds that facilitate chemical reactions such as aldol condensations[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide.